Related Experiment Videos
Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Sang-Jin Lee1, Yanping Zhang, Sang Don Lee
1Department of Urology, Indiana University, Indianapolis, IN 46202, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|November 27, 2004
Summary
Researchers developed a novel oncolytic adenovirus therapy targeting hormone-independent prostate cancer. This therapy specifically replicates in prostate cancer cells, leading to tumor cell death and significant tumor growth delay in preclinical models.
Area of Science:
- Oncolytic virology
- Prostate cancer therapeutics
- Gene therapy
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Hormone-independent prostate cancer is difficult to treat.
- Targeted therapies are needed for advanced prostate cancer.
Purpose of the Study:
- To investigate the efficacy of a prostate-specific replication-competent adenovirus for treating hormone-independent prostate cancer.
- To evaluate the targeting capability of the engineered adenovirus using a prostate-specific enhancer element (PSME).
Main Methods:
- Constructed a recombinant adenovirus (Ad5-PSME-E1a) with a prostate-specific enhancer (PSME) controlling viral E1A expression.
- Assessed viral replication and E1A protein expression in PSMA-positive and PSMA-negative prostate cancer cell lines.
- Performed in vitro cell killing assays and in vivo xenograft studies in nude mice.
Main Results:
- Ad5-PSME-E1a demonstrated high E1A expression and efficient replication in PSMA-positive prostate cancer cells (C4-2, CWR22rv).
- Replication was significantly attenuated in PSMA-negative cells (PC-3, A549).
- In vitro, Ad5-PSME-E1a effectively lysed prostate cancer cells, with minimal toxicity to PSMA-negative cells.
- In vivo, Ad5-PSME-E1a treatment significantly delayed tumor growth and induced necrosis in a CWR22rv xenograft model.
Conclusions:
- PSME-driven replication-competent adenovirus shows promise as a targeted therapeutic strategy for hormone-independent prostate cancer.
- This approach offers a potential new treatment option for patients who have undergone hormone ablation therapy.